首页> 外文OA文献 >Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene

【2h】

Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene

机译：随机相1初步试验的安全性和免疫原性与Alvac-HIV（VCP205）和来自HIV-1菌株Mn和Lai-2的低聚糖蛋白160在明矾或多磷腈中佐剂

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Robert J. OConnell; Jean-Louis Excler; Victoria R. Polonis; Silvia Ratto-Kim; Josephine Cox; Linda L. Jagodzinski; Michelle Liu; Lindsay Wieczorek; John G. McNeil; Raphaelle El-Habib; Nelson L. Michael; Bruce L. Gilliam; Robert Paris; Thomas C. VanCott; Georgia D. Tomaras; Deborah L. Birx; Merlin L. Robb; Jerome H. Kim;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene [J] . OConnell Robert J., Excler Jean-Louis, Polonis Victoria R., The Journal of Infectious Diseases . 2016 ,第12期

机译：安全性和免疫原性的ALVAC-HIV（vCP205）和寡糖糖蛋白160来自HIV-1菌株MN和LAI-2的明矾或聚磷腈佐剂的随机1期初次增强试验
2. Safety and immunogenicity of a randomized phase I prime-boost trial with ALVAC-HIV (vCP205) and gp160 MN/LAI-2 adjuvanted in alum or polyphosphazene [J] . RJ O’Connell, VR Polonis, S Ratto-Kim, Retrovirology . 2012 ,第S2期

机译：使用ALVAC-HIV（vCP205）和gp160 MN / LAI-2佐以明矾或聚磷腈的随机I期初免-加强试验的安全性和免疫原性
3. Safety and immunogenicity of a randomized phase I prime-boost trial with ALVAC-HIV (vCP205) and gp160 MN/LAI-2 adjuvanted in alum or polyphosphazene [J] . RJ O’Connell, VR Polonis, S Ratto-Kim, Retrovirology . 2012 ,第S2期

机译：使用ALVAC-HIV（vCP205）和gp160 MN / LAI-2佐以明矾或聚磷腈的随机I期初免-加强试验的安全性和免疫原性
4. A double-blind, randomized phase II trial of thesafety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adults [C] . Shelly A. McNeil, Scott A. Halperin, Joanne M. Langley, Lancefield International Symposium on Streptococci and Streptococcal Diseases . 2006

机译：一种双盲，随机期II试验，对健康成人的26岁的26岁群体的疫苗疫苗
5. Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene [O] . Robert J. OConnell, Jean-Louis Excler, Victoria R. Polonis, -1

机译：安全性和免疫原性的ALVAC-HIV（vCP205）和寡糖糖蛋白160来自HIV-1菌株MN和LAI-2的明矾或聚磷腈佐剂的随机1期初免-加强试验
6. Safety and immunogenicity of a randomized phase I prime-boost trial with ALVAC-HIV (vCP205) and gp160 MN/LAI-2 adjuvanted in alum or polyphosphazene [O] . 2012

机译：使用ALVAC-HIV（vCP205）和gp160 MN / LAI-2佐以明矾或聚磷腈的随机I期初免-加强试验的安全性和免疫原性

Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene

著录项

相似文献

相关主题

期刊订阅